AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
+4.09%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$306M
AUM Growth
+$306M
(+20%)
Cap. Flow
+$17M
Cap. Flow
% of AUM
5.56%
Top 10 Holdings %
Top 10 Hldgs %
50.4%
Holding
90
New
22
Increased
26
Reduced
13
Closed
13
Top Buys
| 1 |
Apogee Therapeutics
APGE
|
$22.3M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
$13.4M |
| 3 |
Xenon Pharmaceuticals
XENE
|
$8.2M |
| 4 |
Krystal Biotech
KRYS
|
$6.67M |
| 5 |
Arcellx
ACLX
|
$6.23M |
Top Sells
| 1 |
Spyre Therapeutics
SYRE
|
$57.1M |
| 2 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$12.3M |
| 3 |
Biogen
BIIB
|
$11.4M |
| 4 |
Ventyx Biosciences
VTYX
|
$3.3M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$2.97M |
Sector Composition
| 1 | Healthcare | 94.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Apogee Therapeutics
APGE
$2.17B
| $22.3M | 6.26% | +1,045,110 | New | +$22.3M |
|
2
Teva Pharmaceuticals
TEVA
$21.1B
| $20.4M | 5.74% | 2,000,000 +400,000 | +25% | +$4.08M |
|
|
CBAY
3
DELISTED
Cymabay Therapeutics
CBAY
| $16.8M | 4.74% | 1,129,376 +79,258 | +8% | +$1.18M |
|
|
CERE
4
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $15M | 4.21% | 685,061 +135,061 | +25% | +$2.95M |
|
|
5
Arcellx
ACLX
$3.85B
| $14.4M | 4.04% | 400,000 +173,725 | +77% | +$6.23M |
|
|
6
Crinetics Pharmaceuticals
CRNX
$2.92B
| $13.4M | 3.76% | +450,000 | New | +$13.4M |
|
7
Madrigal Pharmaceuticals
MDGL
$9.76B
| $12.4M | 3.49% | 85,000 -7,500 | -8% | -$1.1M |
|
8
Establishment Labs
ESTA
$1.2B
| $11.7M | 3.3% | 239,108 +27,500 | +13% | +$1.35M |
|
9
Immunovant
IMVT
$2.56B
| $11.5M | 3.24% | 300,000 +40,000 | +15% | +$1.54M |
|
|
10
Xenon Pharmaceuticals
XENE
$2.98B
| $10.3M | 2.89% | 300,438 +240,062 | +398% | +$8.2M |
|
11
Kura Oncology
KURA
$686M
| $7.81M | 2.2% | 856,535 -53,782 | -6% | -$490K |
|
12
Astria Therapeutics
ATXS
$349M
| $7.46M | 2.1% | 1,000,300 +349,425 | +54% | +$2.61M |
|
13
Cytokinetics
CYTK
$4.23B
| $6.79M | 1.91% | 230,366 +105,218 | +84% | +$3.1M |
|
|
14
Krystal Biotech
KRYS
$4.27B
| $6.67M | 1.88% | +57,500 | New | +$6.67M |
|
|
CNTA
15
Centessa Pharmaceuticals
CNTA
$2.25B
| $6.59M | 1.85% | 1,018,091 +117,368 | +13% | +$759K |
|
|
MORF
16
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $6.19M | 1.74% | 270,000 +68,113 | +34% | +$1.56M |
|
|
VRNA
17
Verona Pharma
VRNA
$9.16B
| $6M | 1.69% | 368,329 -79,338 | -18% | -$1.29M |
|
|
INZY
18
DELISTED
Inozyme Pharma
INZY
| $5.8M | 1.63% | 1,379,852 +628,056 | +84% | +$2.64M |
|
|
AUTL
19
Autolus Therapeutics
AUTL
$399M
| $4.64M | 1.31% | 1,992,466 +403,449 | +25% | +$940K |
|
20
Savara
SVRA
$567M
| $4.35M | 1.22% | +1,150,000 | New | +$4.35M |
|
21
Ascendis Pharma
ASND
$11.8B
| $4.34M | 1.22% | 46,400 -11,360 | -20% | -$1.06M |
|
22
Celldex Therapeutics
CLDX
$1.47B
| $4.13M | 1.16% | 150,000 +62,969 | +72% | +$1.73M |
|
23
AstraZeneca
AZN
$248B
| $4.06M | 1.14% | 60,000 | – | – |
|
24
Tango Therapeutics
TNGX
$747M
| $3.94M | 1.11% | +350,000 | New | +$3.94M |
|
25
Prothena Corp
PRTA
$441M
| $3.82M | 1.08% | 79,214 -20,786 | -21% | -$1M |
|